A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy
- 14 March 2011
- journal article
- letter
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 127 (5), 1309-1310.e1
- https://doi.org/10.1016/j.jaci.2011.01.051
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Oral peanut immunotherapy in children with peanut anaphylaxisJournal of Allergy and Clinical Immunology, 2010
- Clinical efficacy and immune regulation with peanut oral immunotherapyJournal of Allergy and Clinical Immunology, 2009
- Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance SystemJournal of Allergy and Clinical Immunology, 2008
- Peanut allergy: Emerging concepts and approaches for an apparent epidemicJournal of Allergy and Clinical Immunology, 2007
- Food anaphylaxisClinical and Experimental Allergy, 2007
- Effect of Anti-IgE Therapy in Patients with Peanut AllergyNew England Journal of Medicine, 2003
- The impact of childhood food allergy on quality of lifeAnnals of Allergy, Asthma & Immunology, 2001